Despite the number of therapy options available, advanced or metastatic HR-positive / HER2-negative breast cancer remains incurable and a major cause of mortality and morbidity in women. Later-line therapies that can be used following the development of hormone resistance are greatly needed. Although the recent introduction of targeted therapies such as Piqray (Novartis) have improved patient outcomes, several treatment gaps remain. Emerging therapies such as elacestrant (Radius Health) and sacituzumab govitecan (Immunomedics) are poised to launch in the near term, boosting competition in an already crowded market. As this competition intensifies, novel therapies should address the remaining unmet needs in the treatment of advanced or metastatic HR-positive / HER2-negative breast cancer to differentiate themselves from their rivals.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2020.
Key companies: Onyx Pharmaxeauticals / Pfizer, Novartis, Eli Lilly, AstraZeneca, Abbott Laboratories.
Key drugs: Ibrance, Kisqali, Verzenio, Piqray, Faslodex, Afinitor, letrozole, anastrozole, and exemestane.